Synagis is supplied in single use vials containing either 50 mg or 100 mg of lyophilized product.
Vials are for single-use only.
After opening, use within six hours and discard any unused drug. The IMpact-RSV Study Group. Palivizumab, a Humanized RSV Monoclonal Antibody, Reduces Hospitalization from RSV Infection in High-Risk Infants. The two groups were well matched. Ninety-nine percent of the patients completed this trial.